Ublituximab(LFB-R603, EMAB-6)Phase I  GTC Bio therapeutics,LFB BiotechnologiesType ImAb  Chimeric; IgG1Glycoengineered  Ublituximab, (12 patients of Advanced CLL, ORR 35%) [102]  High ADCC